Patients with psoriatic arthritis who are not eligible for randomised controlled trials for TNF inhibitors have treatment response and drug survival similar to those who are eligible.
To access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked Download OBJECTIVES: To determine in a retrospective cohort whether patients with psoriatic arthritis (PsA) who would not have...
Published in: | RMD Open |
---|---|
Main Authors: | , , , , , , |
Other Authors: | |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
BMJ Publishing Group
2019
|
Subjects: | |
Online Access: | http://hdl.handle.net/2336/621198 https://doi.org/10.1136/rmdopen-2019-000984 |
id |
ftlandspitaliuni:oai:www.hirsla.lsh.is:2336/621198 |
---|---|
record_format |
openpolar |
spelling |
ftlandspitaliuni:oai:www.hirsla.lsh.is:2336/621198 2023-05-15T16:52:47+02:00 Patients with psoriatic arthritis who are not eligible for randomised controlled trials for TNF inhibitors have treatment response and drug survival similar to those who are eligible. Palsson, Olafur Love, Thorvardur Jon Gunnarsdottir, Anna Ingibjorg Gunnarsson, Petur Sigurdur Runarsdottir, Eydis Erla Krogh, Niels Steen Gudbjornsson, Bjorn 1 Centre for Rheumatology Research, Landspitali University Hospital, Reykjavik, Iceland. 2 Department of Science and Research, Landspitali University Hospital, Reykjavik, Iceland. 3 Faculty of Medicine, University of Iceland, Reykjavik, Iceland. 4 Faculty of Pharmaceutical Sciences, University of Iceland, Reykjavik, Iceland. 5 Hospital Pharmacy, Landspitali University Hospital, Reykjavik, Iceland. 6 Zitelab Aps, Copenhagen, Denmark. 2019-12 http://hdl.handle.net/2336/621198 https://doi.org/10.1136/rmdopen-2019-000984 en eng BMJ Publishing Group https://rmdopen.bmj.com/content/5/2/e000984 Palsson O, Love TJ, Gunnarsdottir AI, Gunnarsson PS, Runarsdottir EE, Krogh NS, Gudbjornsson B. Patients with psoriatic arthritis who are not eligible for randomised controlled trials for TNF inhibitors have treatment response and drug survival similar to those who are eligible. RMD open. 2019 Jul 1;5(2):e000984. 2056-5933 31413869 doi:10.1136/rmdopen-2019-000984 http://hdl.handle.net/2336/621198 RMD Open Open Access - Opinn aðgangur RMD open DMARDs (biologic) anti-tnf arthritis outcomes research psoriatic arthritis Infliximab Psoriatic Article 2019 ftlandspitaliuni https://doi.org/10.1136/rmdopen-2019-000984 2022-05-29T08:22:29Z To access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked Download OBJECTIVES: To determine in a retrospective cohort whether patients with psoriatic arthritis (PsA) who would not have fulfilled the inclusion criteria for randomised controlled trials (RCTs) for the TNF inhibitor (TNFi) chosen for their treatment (excl) have similar benefits and drug survival as those patients who would have (incl). METHODS: All patients with rheumatic disorders who are treated with biological disease-modifying antirheumatic drugs in Iceland are registered in ICEBIO. On 1 February 2016, 329 individuals with PsA were registered in ICEBIO, of whom 231 had data available for their first start of TNFi and could be evaluated according to the inclusion criteria of the respective RCTs. Disease activity was collected at baseline using Visual Analogue Scale (pain, fatigue and global (patient and physician) assessments), swollen joint count (SJC) and tender joint count (TJC), Disease Activity Score 28-joint count C reactive protein (DAS28-CRP) and Health Assessment Questionnaire (HAQ). Treatment response was measured at 6 and 18 months according to American College of Rheumatology response criteria, DAS28-CRP and Disease Activity Score in Psoriatic Arthritis for 28 joints. Drug survival rate was also analysed. RESULTS: The demographics of these two groups were similar at baseline, although the incl group had higher SJC (5.5 vs 3.8) and subsequently higher DAS28-CRP (4.6 vs 4.2). While a larger change in disease activity was observed in the incl group with respect to HAQ and SJC, both groups had similar disease activity at follow-up. Drug survival was similar in both groups. CONCLUSIONS: Patients with PsA who would not have fulfilled the inclusion criteria in RCTs reach similar disease activity scores at follow-up of 6 and 18 months and have similar drug survival as those patients who would have been included in RCTs. NordForsk ... Article in Journal/Newspaper Iceland Hirsla - Landspítali University Hospital research archive RMD Open 5 2 e000984 |
institution |
Open Polar |
collection |
Hirsla - Landspítali University Hospital research archive |
op_collection_id |
ftlandspitaliuni |
language |
English |
topic |
DMARDs (biologic) anti-tnf arthritis outcomes research psoriatic arthritis Infliximab Psoriatic |
spellingShingle |
DMARDs (biologic) anti-tnf arthritis outcomes research psoriatic arthritis Infliximab Psoriatic Palsson, Olafur Love, Thorvardur Jon Gunnarsdottir, Anna Ingibjorg Gunnarsson, Petur Sigurdur Runarsdottir, Eydis Erla Krogh, Niels Steen Gudbjornsson, Bjorn Patients with psoriatic arthritis who are not eligible for randomised controlled trials for TNF inhibitors have treatment response and drug survival similar to those who are eligible. |
topic_facet |
DMARDs (biologic) anti-tnf arthritis outcomes research psoriatic arthritis Infliximab Psoriatic |
description |
To access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked Download OBJECTIVES: To determine in a retrospective cohort whether patients with psoriatic arthritis (PsA) who would not have fulfilled the inclusion criteria for randomised controlled trials (RCTs) for the TNF inhibitor (TNFi) chosen for their treatment (excl) have similar benefits and drug survival as those patients who would have (incl). METHODS: All patients with rheumatic disorders who are treated with biological disease-modifying antirheumatic drugs in Iceland are registered in ICEBIO. On 1 February 2016, 329 individuals with PsA were registered in ICEBIO, of whom 231 had data available for their first start of TNFi and could be evaluated according to the inclusion criteria of the respective RCTs. Disease activity was collected at baseline using Visual Analogue Scale (pain, fatigue and global (patient and physician) assessments), swollen joint count (SJC) and tender joint count (TJC), Disease Activity Score 28-joint count C reactive protein (DAS28-CRP) and Health Assessment Questionnaire (HAQ). Treatment response was measured at 6 and 18 months according to American College of Rheumatology response criteria, DAS28-CRP and Disease Activity Score in Psoriatic Arthritis for 28 joints. Drug survival rate was also analysed. RESULTS: The demographics of these two groups were similar at baseline, although the incl group had higher SJC (5.5 vs 3.8) and subsequently higher DAS28-CRP (4.6 vs 4.2). While a larger change in disease activity was observed in the incl group with respect to HAQ and SJC, both groups had similar disease activity at follow-up. Drug survival was similar in both groups. CONCLUSIONS: Patients with PsA who would not have fulfilled the inclusion criteria in RCTs reach similar disease activity scores at follow-up of 6 and 18 months and have similar drug survival as those patients who would have been included in RCTs. NordForsk ... |
author2 |
1 Centre for Rheumatology Research, Landspitali University Hospital, Reykjavik, Iceland. 2 Department of Science and Research, Landspitali University Hospital, Reykjavik, Iceland. 3 Faculty of Medicine, University of Iceland, Reykjavik, Iceland. 4 Faculty of Pharmaceutical Sciences, University of Iceland, Reykjavik, Iceland. 5 Hospital Pharmacy, Landspitali University Hospital, Reykjavik, Iceland. 6 Zitelab Aps, Copenhagen, Denmark. |
format |
Article in Journal/Newspaper |
author |
Palsson, Olafur Love, Thorvardur Jon Gunnarsdottir, Anna Ingibjorg Gunnarsson, Petur Sigurdur Runarsdottir, Eydis Erla Krogh, Niels Steen Gudbjornsson, Bjorn |
author_facet |
Palsson, Olafur Love, Thorvardur Jon Gunnarsdottir, Anna Ingibjorg Gunnarsson, Petur Sigurdur Runarsdottir, Eydis Erla Krogh, Niels Steen Gudbjornsson, Bjorn |
author_sort |
Palsson, Olafur |
title |
Patients with psoriatic arthritis who are not eligible for randomised controlled trials for TNF inhibitors have treatment response and drug survival similar to those who are eligible. |
title_short |
Patients with psoriatic arthritis who are not eligible for randomised controlled trials for TNF inhibitors have treatment response and drug survival similar to those who are eligible. |
title_full |
Patients with psoriatic arthritis who are not eligible for randomised controlled trials for TNF inhibitors have treatment response and drug survival similar to those who are eligible. |
title_fullStr |
Patients with psoriatic arthritis who are not eligible for randomised controlled trials for TNF inhibitors have treatment response and drug survival similar to those who are eligible. |
title_full_unstemmed |
Patients with psoriatic arthritis who are not eligible for randomised controlled trials for TNF inhibitors have treatment response and drug survival similar to those who are eligible. |
title_sort |
patients with psoriatic arthritis who are not eligible for randomised controlled trials for tnf inhibitors have treatment response and drug survival similar to those who are eligible. |
publisher |
BMJ Publishing Group |
publishDate |
2019 |
url |
http://hdl.handle.net/2336/621198 https://doi.org/10.1136/rmdopen-2019-000984 |
genre |
Iceland |
genre_facet |
Iceland |
op_source |
RMD open |
op_relation |
https://rmdopen.bmj.com/content/5/2/e000984 Palsson O, Love TJ, Gunnarsdottir AI, Gunnarsson PS, Runarsdottir EE, Krogh NS, Gudbjornsson B. Patients with psoriatic arthritis who are not eligible for randomised controlled trials for TNF inhibitors have treatment response and drug survival similar to those who are eligible. RMD open. 2019 Jul 1;5(2):e000984. 2056-5933 31413869 doi:10.1136/rmdopen-2019-000984 http://hdl.handle.net/2336/621198 RMD Open |
op_rights |
Open Access - Opinn aðgangur |
op_doi |
https://doi.org/10.1136/rmdopen-2019-000984 |
container_title |
RMD Open |
container_volume |
5 |
container_issue |
2 |
container_start_page |
e000984 |
_version_ |
1766043201477541888 |